HomeInsightsStock Comparison

Aarti Drugs Ltd vs Zydus Lifesciences Ltd Stock Comparison

Aarti Drugs Ltd vs Zydus Lifesciences Ltd Stock Comparison

Last Updated on: Jul 16, 2025

Key Highlights

  • The Latest Trading Price of Aarti Drugs Ltd is ₹ 521.45 as of 16 Jul 15:13.
  • The P/E Ratio of Aarti Drugs Ltd changed from 8.3 on March 2020 to 23.3 on March 2024 . This represents a CAGR of 22.93% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 26.2 on March 2024 . This represents a CAGR of 2.37% over 5 years.
  • The Market Cap of Aarti Drugs Ltd changed from ₹ 1178 crore on March 2020 to ₹ 3988 crore on March 2024 . This represents a CAGR of 27.61% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 27344 crore on March 2020 to ₹ 101151 crore on March 2024 . This represents a CAGR of 29.90% over 5 years.
  • The revenue of Aarti Drugs Ltd for the Mar '25 is ₹ 678.63 crore as compare to the Dec '24 revenue of ₹ 568.5 crore. This represent the growth of 19.37% The revenue of Zydus Lifesciences Ltd for the Mar '25 is ₹ 6608 crore as compare to the Dec '24 revenue of ₹ 5326 crore. This represent the growth of 24.07%.
  • The ebitda of Aarti Drugs Ltd for the Mar '25 is ₹ 95.2 crore as compare to the Dec '24 ebitda of ₹ 73.62 crore. This represent the growth of 29.31% The ebitda of Zydus Lifesciences Ltd for the Mar '25 is ₹ 1986 crore as compare to the Dec '24 ebitda of ₹ 1444 crore. This represent the growth of 37.49%.
  • The net profit of Aarti Drugs Ltd changed from ₹ 47.97 crore to ₹ 62.77 crore over 8 quarters. This represents a CAGR of 14.39% The net profit of Zydus Lifesciences Ltd changed from ₹ 1112 crore to ₹ 1248 crore over 8 quarters. This represents a CAGR of 5.97% .
  • The Dividend Payout of Aarti Drugs Ltd changed from 3.43 % on March 2020 to 6.48 % on March 2024 . This represents a CAGR of 13.57% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 25.37 % on March 2020 to 8.77 % on March 2024 . This represents a CAGR of -19.14% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aarti Drugs Ltd

  • Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals.
  • The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million.
  • With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.
  • It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra.
  • It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary).

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
  • The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Aarti Drugs Ltd News Hub

News

Aarti Drugs to convene board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 18 July 2025. ...

Read more

16 Jul 2025 10:24

News

Aarti Drugs to convene board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 6 May 2025. Po...

Read more

30 Apr 2025 11:38

News

Aarti Drugs receives affirmation in credit ratings from ICRA

Aarti Drugs has received reaffirmation in credit rating at ICRA AA-; Stable/ ICRA A1+ for ...

Read more

31 Jan 2025 19:10

News

Aarti Drugs gains as PAT rises to Rs 37 cr in Q3; declares dividend of Re 1/sh

Revenue from operations declined 6.44% to Rs 568.50 crore in third quarter of FY25 as comp...

Read more

30 Jan 2025 12:14

News

Board of Aarti Drugs recommends Interim Dividend

Aarti Drugs announced that the Board of Directors of the Company at its meeting held on 29...

Read more

29 Jan 2025 17:03

News

Aarti Drugs to conduct board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 29 January 202...

Read more

23 Jan 2025 11:25

Zydus Lifesciences Ltd News Hub

News

Zydus Lifesciences gets USFDA Nod for Celecoxib Capsules

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones ...

Read more

15 Jul 2025 15:45

News

Zydus Life Matoda facility receives two observations from USFDA after inspection

In a regulatory filing, the company confirmed that the USFDA conducted a follow-up inspect...

Read more

19 Jun 2025 09:50

News

Zydus Lifesciences appoints Managing Director

Zydus Lifesciences has approved the appointment of s. Swati Dalal as the Additional Direct...

Read more

16 Jun 2025 14:16

News

Zydus Life subsidiary ZHL appoints Swati Dalal as MD

The appointment was approved by the nomination and remuneration committee (NRC). Swati Dal...

Read more

16 Jun 2025 14:42

News

Zydus Life receives USFDA EIR for Gujarat facility

The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the r...

Read more

12 Jun 2025 09:55

News

Zydus' Ankleshwar API unit clears USFDA inspection

Zydus Lifesciences has received the Establishment Inspection Report (EIR) report from the ...

Read more

12 Jun 2025 10:41

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

SWOT Analysis Of Aarti Drugs Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Zydus Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Aarti Drugs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aarti Drugs Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Aarti Drugs Ltd or Zydus Lifesciences Ltd?

Market cap of Aarti Drugs Ltd is 4,873 Cr while Market cap of Zydus Lifesciences Ltd is 97,317 Cr

What are the key factors driving the stock performance of Aarti Drugs Ltd and Zydus Lifesciences Ltd?

The stock performance of Aarti Drugs Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Drugs Ltd and Zydus Lifesciences Ltd?

As of July 16, 2025, the Aarti Drugs Ltd stock price is INR ₹530.1. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹967.15.

How do dividend payouts of Aarti Drugs Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Aarti Drugs Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions